The Combating Counterfeit Pharmaceuticals Act of 2025 aims to strengthen the existing Fentanyl Sanctions Act by addressing the trafficking of counterfeit drugs and copy-cat ingredients. The primary goal is to enhance the regulation and enforcement against these dangerous substances, which pose significant health risks to the public. Key provisions of the Act include new definitions for "copy-cat ingredients" and "counterfeit drugs." A copy-cat ingredient is defined as one that mimics an approved drug but is made using different processes or is of lower quality.